PODD vs SNN: Insulet and Smith & Nephew SNATS compared
The short version
From the latest prices and each company's SEC filings. Who's ahead on each measure, not which to buy.
- Smith & Nephew SNATS is the larger company, worth $12.0B, about 1.2 times Insulet.
- Insulet grew revenue faster over the last year (+23.5% vs +6.1%).
- Insulet keeps more of each dollar of revenue as operating profit (16.9% vs 12.9%).
- On earnings, Insulet is the cheaper stock (32.8x vs 37.8x).
- Insulet's price assumes faster free cash flow growth: about 9% a year, against 0% for Smith & Nephew SNATS (reverse DCF).
Side by side
The stronger figure is shaded where higher (or, for valuation multiples, lower) reads as better. How the implied growth works.
| Measure | PODD | SNN |
|---|---|---|
| Market cap | $9.7B | $12.0B |
| Share price | $135.28 | $27.24 |
| Revenue (last fiscal year) | $2.7B | $6.2B |
| Free cash flow (last fiscal year) | $358M | $852M |
| Revenue growth, last year | +23.5% | +6.1% |
| Revenue growth per year, last 5 fiscal years | +27.0% | +4.3% |
| Operating margin | 16.9% | 12.9% |
| Net margin | 12.3% | 10.1% |
| Return on equity | 26.4% | 11.8% |
| P/E (trailing) | 32.8x | 37.8x |
| Price / free cash flow | 25.8x | 14.0x |
| EV / EBITDA | 14.9x | 10.3x |
| FCF growth the price implies | 9.0% | 0.37% |
| Dividend yield | — | 2.8% |
| Debt / equity | 1.23x | 0.98x |
| Fundamental grade | B | B |
| Superinvestors holding it | 5 | 2 |
| Insider purchases, last 12 months | 3 | 0 |
Results from SEC filings
Revenue and free cash flow by fiscal year, from each company's 10-K filings.
Insulet
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $1.0B | -$191M | 12.1% |
| 2022 | $1.1B | -$17M | 3.6% |
| 2023 | $1.7B | $62M | 13.0% |
| 2024 | $2.1B | $296M | 14.9% |
| 2025 | $2.7B | $358M | 17.5% |
Smith & Nephew SNATS
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $5.2B | $469M | 11.4% |
| 2022 | $5.2B | $110M | 8.6% |
| 2023 | $5.5B | $181M | 7.7% |
| 2024 | $5.8B | $606M | 11.3% |
| 2025 | $6.2B | $852M | 12.9% |
Where the revenue comes from
Insulet · by products, 2025
U.S.$1.9B71%
International$754M28%
Drug Delivery$34M1%
Smith & Nephew SNATS · by segments, 2025
Orthopaedics$2.4B40%
Sports Medicine & ENT$1.9B31%
Advanced Wound Management$1.8B29%
Compare them in fullFifteen years of statements, quarterly results, DCF and IRR models, and any number of peers side by side.
Open PODD in InvestinglyQuestions
Which is bigger, Insulet or Smith & Nephew SNATS?
Smith & Nephew SNATS (SNN), at $12.0B against $9.7B.
Is PODD or SNN cheaper?
By trailing P/E, Insulet (32.8x) is cheaper than Smith & Nephew SNATS (37.8x). A lower multiple can also mean the market expects less growth.
Which grows faster, PODD or SNN?
Insulet: revenue grew +23.5% over the last year, against +6.1%.
More comparisons
Prices and ratios as of the last daily update; statements from SEC filings. Information only, not investment advice.